Results 171 to 180 of about 297,910 (307)

Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Axial postural abnormalities (APAs) are common, disabling complications of Parkinson's disease (PD) with unclear pathophysiology. The presence of hyperactivity in multiple trunk muscles supports the use of botulinum toxin (BTA). However, its application is complex, due to the lack of standardized clinical and electrophysiological ...
Giacomo Argenziano, Giovanna Squintani, Serena Camozzi, Ilaria Di Vico, Marialuisa Gandolfi, Carlo Alberto Artusi, Michele Tinazzi, Christian Geroin   +7 more
wiley   +1 more source

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.
Hikaru Kamo, Genko Oyama, Mai Shimizu, Haruka Takeshige‐Amano, Takashi Ogawa, Wataru Sako, Noriko Nishikawa, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Nobutaka Hattori   +14 more
wiley   +1 more source

VTA-forebrain connectivity moderates adaptive behavior. [PDF]

Brain Struct Funct
Sinza SI, Choi K, Lim IE, Williams MA, Ogundele OM.   +4 more
europepmc   +1 more source

Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visual hallucinations (VH) and mild cognitive impairment (MCI) often co‐occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co‐occurrence, and whether this relationship ...
Sabrina M. Adamo, Vaishali Mutreja, Marta Statucka, Batu Kaya, Taylor W. Schmitz, Anthony C. Ruocco, Melanie Cohn   +6 more
wiley   +1 more source

N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in Parkinson's disease models. [PDF]

J Clin Invest
Song P, Chen C, Franchini R, Duong B, Wang YZ, Coukos R, Xie Z, Savas JN, Zhou Y, Bertoldi M, Surmeier DJ, Parisiadou L, Krainc D.   +12 more
europepmc   +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete, Christian Mattjie, Brook Huxford, Jonathan P. Bestwick, Alastair J. Noyce, Cristina Simonet   +5 more
wiley   +1 more source

Evaluation of a commercial AI-assisted cell counting software for dopaminergic neurons across species. [PDF]

PLoS One
Kunugitani K, Sawamura M, Taguchi T, Hirato T, Uemura N, Ayaki T, Nakanishi E, Yamakado H, Ishimoto T, Onoe H, Isa T, Matsumoto R, Takahashi R.   +12 more
europepmc   +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Speech Impairment in Early Parkinson's Disease Is Associated with Nigrostriatal Dopaminergic Dysfunction. [PDF]

J Clin Med
Polychronis S, Nasios G, Dardiotis E, Akande R, Pagano G.   +4 more
europepmc   +1 more source

Brain Imaging Changes Following Deep Brain Stimulation Patients with Parkinson's Disease: A Literature Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's Disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Structural brain changes, including atrophy in the midbrain, basal ganglia, and cortical regions such as the frontal and temporal lobes, are observed in advanced stages.
Suraiya Mangra, Stanislaw Szlufik, Chao‐Kai Hu, Alexandre Boutet, Jürgen Germann, Andres M. Lozano   +5 more
wiley   +1 more source